Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. by Bonnefoi, H. et al.
Annals of Oncology 25: 1128–1136, 2014
doi:10.1093/annonc/mdu118
Published online 11 March 2014
Pathological complete response after neoadjuvant
chemotherapy is an independent predictive factor
irrespective of simpliﬁed breast cancer intrinsic
subtypes: a landmark and two-step approach analyses
from the EORTC 10994/BIG 1-00 phase III trial
H. Bonnefoi1*, S. Litière2, M. Piccart3, G. MacGrogan1, P. Fumoleau4, E. Brain5, T. Petit6,
P. Rouanet7, J. Jassem8, C. Moldovan9, A. Bodmer10,11, K. Zaman12, T. Cufer13,14,
M. Campone15,16, E. Luporsi17, P. Malmström18,19, G. Werutsky2, J. Bogaerts2, J. Bergh20,21 &
D. A. Cameron22,23 on behalf of the EORTC 10994/BIG 1-00 Study investigators
1Department of Medical Oncology, Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U916, Bordeaux, France; 2European Organisation
for Research and Treatment of Cancer (EORTC), Brussels; 3Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 4Centre George-François Leclerc, Dijon;
5Ensemble Hospitalier de L’Institut Curie, Hopital René Huguenin, St-Cloud; 6Centre Paul Strauss, Strasbourg; 7Centre Val D’Aurelle-Paul Lamarque, Montpellier, France;
8Medical University, Gdansk, Poland; 9Centre Henri Becquerel, Rouen, France; 10Geneva University Hospital, Geneva; 11Swiss Group for Clinical Cancer Research (SAKK),
Bern; 12Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; 13Institute of Oncology, Ljubljana; 14University Clinic Golnik, Golnik, Slovenia; 15Institut de
Cancérologie de L’Ouest (ICO), Centre René Gauducheau, Nantes; 16Centre Paul Papin, Angers; 17Centre Alexis Vautrin, Nancy, France; 18Department of Clinical Sciences,
Lund University, Lund; 19Skåne Department of Oncology, Skåne University Hospital, Lund; 20Swedish Breast Cancer Group (SweBCG), Stockholm; 21Department of
Oncology, Karolinska Institutet, Radiumhemmet and Karolinska University Hospital, Stockholm, Sweden; 22Cancer Services, Edinburgh University; 23Anglo-Celtic
Cooperative Oncology Group (ACCOG), Edinburgh, UK
Received 20 November 2013; revised 6 February 2014; accepted 6 March 2014
Background: Pathological complete response (pCR) following chemotherapy is strongly associated with both breast
cancer subtype and long-term survival. Within a phase III neoadjuvant chemotherapy trial, we sought to determine
whether the prognostic implications of pCR, TP53 status and treatment arm (taxane versus non-taxane) differed between
intrinsic subtypes.
Patients and methods: Patients were randomized to receive either six cycles of anthracycline-based chemotherapy or
three cycles of docetaxel then three cycles of eprirubicin/docetaxel (T-ET). pCR was deﬁned as no evidence of residual in-
vasive cancer (or very few scattered tumour cells) in primary tumour and lymph nodes. We used a simpliﬁed intrinsic sub-
types classiﬁcation, as suggested by the 2011 St Gallen consensus. Interactions between pCR, TP53 status, treatment
arm and intrinsic subtype on event-free survival (EFS), distant metastasis-free survival (DMFS) and overall survival (OS)
were studied using a landmark and a two-step approach multivariate analyses.
Results: Sufﬁcient data for pCR analyses were available in 1212 (65%) of 1856 patients randomized. pCR occurred in
222 of 1212 (18%) patients: 37 of 496 (7.5%) luminal A, 22 of 147 (15%) luminal B/HER2 negative, 51 of 230 (22%)
luminal B/HER2 positive, 43 of 118 (36%) HER2 positive/non-luminal, 69 of 221(31%) triple negative (TN). The prognostic
effect of pCR on EFS did not differ between subtypes and was an independent predictor for better EFS [hazard ratio
(HR) = 0.40, P < 0.001 in favour of pCR], DMFS (HR = 0.32, P < 0.001) and OS (HR = 0.32, P < 0.001). Chemotherapy
arm was an independent predictor only for EFS (HR = 0.73, P = 0.004 in favour of T-ET). The interaction between TP53,
intrinsic subtypes and survival outcomes only approached statistical signiﬁcance for EFS (P = 0.1).
Conclusions: pCR is an independent predictor of favourable clinical outcomes in all molecular subtypes in a two-step
multivariate analysis.
ClinicalTrials.gov: EORTC 10994/BIG 1-00 Trial registration number NCT00017095.
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introduction
A proportion of breast cancer patients continue to be diagnosed
with large tumours, and despite treatment with neoadjuvant
chemotherapy, have a high rate of relapse as shown in several re-
cently published trials including the EORTC 10994/BIG 1-00
trial [1]. There is growing recognition of the importance of
pathological complete response (pCR) following chemotherapy,
particularly as a surrogate for survival outcomes, and the US
food and drug administration (FDA) is investigating whether
pCR rates could be used to guide drug registration [2].
However, any analysis needs to consider breast cancer hetero-
geneity using for example the intrinsic subtype classiﬁcation [3,
4]. The association between pCR and excellent prognosis has
only been demonstrated for some subtypes such as triple nega-
tive (TN) [5–7] and human epidermal growth factor 2 receptor
(HER2)-positive [7, 8], although with conﬂicting results [6].
Within the context of the EORTC 10994/BIG 1-00 rando-
mized neoadjuvant study, we sought evidence as to whether the
prognostic implications of pCR differed between intrinsic sub-
types, after adjusting for other important prognostic factors.
Additionally, we evaluated the impact of treatment arm (taxane
versus non-taxane), and TP53 status on survival outcomes
among the different molecular subtypes. To address these ques-
tions, we carried out a landmark [9, 10] and a two-step ap-
proach multivariate analyses.
methods
study design, eligibility and treatment
This was a planned secondary analysis of the EORTC 10994/BIG 1-00 trial
which randomized patients between six cycles of 5-ﬂuorouracil, epirubicin
and cyclophosphamide and a taxane-based regimen, docetaxel × three cycles
followed by epirubicin + docetaxel for three cycles, all given before primary
surgery [1]. Eligible patients were women aged <71 years with histologically
proven invasive carcinoma of the breast suitable for neoadjuvant chemother-
apy, with any large operable or locally advanced/inﬂammatory breast cancer.
Patients with HER2-positive tumours were allowed to enter adjuvant clinical
trials assessing trastuzumab or to receive this treatment in the adjuvant
setting once it became standard practice, and none received neoadjuvant
trastuzumab.
The trial was approved by national and/or local ethics committees in all
participating centres. Before registration, all patients gave signed informed
consent for the clinical trial and for research on tumour samples.
For the sub-study that is the subject of this report, a subgroup of the
initial population of 1856 was selected based on the following criteria: (i)
patients with sufﬁcient information available on HER2, ER, PR (progester-
one receptor) and tumour grade to permit a simpliﬁed intrinsic subtype clas-
siﬁcation as deﬁned below; (ii) patients who received at least one cycle of
neoadjuvant chemotherapy and who did not receive radiotherapy before
surgery; (iii) patients without inﬂammatory cancers (T4d). The analysis in-
cluding pathological response was further conﬁned to patients with post-
treatment pathology data and whose tumours did not progress on neoadju-
vant chemotherapy.
objectives
The primary objective of this analysis was to assess the effect of pCR on
event-free survival (EFS) by breast cancer intrinsic subtype (the simpliﬁed
intrinsic subtypes classiﬁcation used in this study is detailed in the pathology
section below), in a two-step multivariate analysis adjusting for important
factors prognostic for EFS, as listed in the statistical section.
Secondary objectives included investigating (i) the effect of TP53 function
on pCR and survival outcomes within each subtype and (ii) the effect of
treatment on survival outcomes across subtypes.
pathology assessment
No central pathology review was carried out for this analysis. Grade, ER, PR
and HER2 status were assessed by local pathologists from a biopsy taken at
diagnosis and prospectively collected in the case report form. ER and PR,
assessed by immunohistochemistry (IHC), were reported as positive or nega-
tive according to each centre’s local deﬁnition. HER2 positivity was deﬁned
as either HER2 gene ampliﬁcation by ﬂuorescent in situ hybridization and/
or scored 3+ by IHC. Because information on Ki-67 was not available from
data collected within the main TP53 study, we replaced Ki-67 by grade in
order to classify tumours in a simpliﬁed intrinsic subtype’s classiﬁcation, as
suggested by the St Gallen 2011 consensus [11]. We used the following clas-
siﬁcation:
• Luminal A-like: ER and/or PR positive, HER2 negative and grade 1 or 2.
• Luminal B-like (HER2 negative): ER and/or PR positive, HER2 negative
and grade 3.
• Luminal B-like (HER2 positive): ER and/or PR positive, HER2 positive
(IHC3+ or ampliﬁed) and any grade (or grade unknown).
• HER2 positive (non-luminal): ER and PR negative, HER2 positive (IHC3+
or ampliﬁed) and any grade (or grade unknown).
• TN: ER and PR negative, HER2 negative and any grade (or grade
unknown).
Pathological response was assessed by local pathologists after completion of
the neoadjuvant chemotherapy. pCR was deﬁned as no evidence of residual
‘invasive cancer’ or very few scattered tumour cells left in the primary breast
tumour—with or without residual ductal carcinoma in situ (DCIS)—and in
the lymph nodes. TP53 status was assessed using a functional test in yeast as
previously described [1].
statistical analysis
A statistical analysis plan was prospectively deﬁned. Eligible patients were
analysed on an intent-to-treat basis. Associations between baseline character-
istics and pCR were evaluated in a multivariate logistic regression model.
Survival times were deﬁned as time from randomization to an event.
In order to investigate the prognostic value of pCR on outcomes, a land-
mark analysis approach was used [9, 10], with the landmark chosen as the
date of surgery. Of note, by deﬁnition, patients who progressed on neoadju-
vant treatment were excluded from this analysis. To address our research
question, the following two-step approach was adopted after adjusting for
important prognostic factors (supplementary Figure S1, available at Annals
of Oncology online): as a ﬁrst-step, the potential effects of the three interac-
tions (pCR and intrinsic subtypes; TP53 status and intrinsic subtypes; treat-
ment arm and intrinsic subtypes) were simultaneously investigated in a
multivariate Cox regression model, adjusting for age at diagnosis, meno-
pausal status, cT stage, cN stage and tumour histology (invasive ductal, inva-
sive lobular or other invasive carcinoma). Interactions with a P value of ≤0.1
were considered signiﬁcant. When a signiﬁcant interaction was observed, the
HRs [99% conﬁdence intervals (CI)] within the different subtypes were
reported. If not, as a second-step, the multivariate model was reﬁtted
without interaction(s) and an overall (i.e. over all intrinsic subtypes) HR
(99% CI) was reported. All non-interactions tests were compared with a
signiﬁcance level α = 0.01.
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results
baseline characteristics by intrinsic subtype
Of the 1856 patients originally randomized, only 1289 were as-
sessable for the relationship between subtype and outcome, and
1212 for the landmark analysis of pCR, subtype and outcome.
The reasons for ineligibility are shown in the Consort diagram
(supplementary Figure S2, available at Annals of Oncology
online). The characteristics of patients included in this sub-
study and those who were excluded were similar (supplementary
Table S1, available at Annals of Oncology online).
The median follow-up was 56 months from randomization
and 51 months from date of surgery. The subtypes repartition is
given on supplementary Table S2, available at Annals of
Oncology online. Among patients with HER-positive tumours,
120 of 365 (33%) received adjuvant trastuzumab and none
received neoadjuvant trastuzumab.
pathological responses by intrinsic subtypes
and TP53 status
A pCR was observed in 222 of 1212 (18%) assessable patients
(Table 1). pCR rates differed signiﬁcantly (P < 0.001) across in-
trinsic subtypes, with the lowest rate for luminal A-like (7.5%)
and the highest rate for HER2+/non-luminal (36%). A multi-
variate logistic regression analysis was carried out to assess
whether these differences persist when adjusting for other
known predictive factors for pCR. First, the effect of two interac-
tions (TP53 and intrinsic subtypes; treatment assigned and in-
trinsic subtypes) on pCR rate was examined, but neither were
signiﬁcant. Next, the effect of TP53 and treatment assigned were
tested, and both were non-signiﬁcant. Only intrinsic subtype
(P < 0.001) and cT stage (P < 0.001) were found to be independ-
ent predictors for pCR (supplementary Table S3, available at
Annals of Oncology online).
survival outcome measures (EFS, DMFS and OS)
by intrinsic subtype
Supplementary Figure S3, available at Annals of Oncology online
shows a signiﬁcant difference in the survival end points accord-
ing to subtype [P < 0.001 for EFS, distant metastasis-free sur-
vival (DMFS) and overall survival (OS)]. Patients in the luminal
A-like group had the best outcome across all three survival mea-
sures [12] despite experiencing the lowest pCR rates (Table 1).
Events contributing to EFS are detailed in supplementary
Table S5, available at Annals of Oncology online.
effect of pCR, TP53 and treatment on EFS across
intrinsic subtypes (landmark analysis)
EFS curves (Figure 1) and univariate analysis (Figures 2 and 3).
There was no evidence of an interaction between subtype and
the prognostic inﬂuence of pCR (P = 0.95) (Figure 2). Overall,
regardless of subtype, pCR was prognostic for EFS (Figure 2).
Furthermore, in the univariate Cox regression models, pCR
predicts for a better EFS in the luminal B/HER2-positive,
HER2-positive/non-luminal and TN breast cancer patients.
Although a similar trend is seen for the other two subtypes, the
effect is neither statistically signiﬁcant on its own nor
signiﬁcantly different from the other subtypes (Figure 2).
Figure 3, limited to those patients with assessable TP53 status,
shows that, within the subtypes, there is no evidence of an inter-
action between TP53 status and pCR (P ranging between 0.51
for HER2 positive/non-luminal and 0.95 for Luminal B/HER2
positive and TN). Although in all subgroups, pCR seems to be
associated with better EFS, this association is signiﬁcant only in
HER2 positive/non-luminal with TP53 wild type and TN with
p53 mutated.
two-step multivariate analysis. First, we tested the effect of the
three interactions (pCR and intrinsic subtypes, TP53 and
intrinsic subtypes and treatment assigned and intrinsic
subtypes) on EFS. Only the interaction between TP53 and
intrinsic subtypes was of borderline statistical signiﬁcance
(P = 0.1), with the two other P values being 0.835 and 0.926,
respectively, indicating that pCR and treatment do not interact
differently with EFS according to subtype. The multivariate
model was thus reﬁtted without the non-signiﬁcant interactions.
Table 2 shows the results of this model, with subtype-speciﬁc
HRs for TP53 and overall HRs for pCR and treatment on EFS.
Both pCR and treatment contribute signiﬁcantly to the overall
prediction of EFS [HR = 0.40, P < 0.001 in favour of pCR, and
HR = 0.73, P = 0.004 in favour of three cycles of docetaxel then
three cycles of eprirubicin/docetaxel (T-ET)].
Table 1. pCR rates by intrinsic subtype
N Non-assessable
patients, N
Patients with pCR
(assessable patients), N
Patients with no pCR
(assessable patients), N
pCR rate (assessable
patients) (%)
Odds ratios
(99% CI)a
Luminal A-like 515 19 37 459 (7.5) 1.00
Luminal B-like (HER2 negative) 154 7 22 125 (15.0) 2.18 (1.04–4.58)
Luminal B-like (HER2 positive) 237 7 51 179 (22.2) 3.54 (1.94–6.45)
HER2 positive (non-luminal) 128 10 43 75 (36.4) 7.11 (3.67–13.8)
Triple negative 255 34 69 152 (31.2) 5.63 (3.16–10.0)
Total 1289 77 222 990 (18.3) P < 0.001b
aConsidering only assessable patients.
bP value for overall test of a difference between subtypes considering only assessable patients using a logistic regression model.
pCR, pathological complete response; CI, conﬁdence interval; HER2, human epidermal growth factor receptor 2.
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discussion
This analysis within a randomized phase III study conﬁrms su-
perior outcomes for those patients whose tumours achieve pCR
in multivariate analysis, with impressive HRs in favour of
patients achieving pCR (0.40, 0.32 and 0.32 for EFS, DMFS and
OS, respectively) (Table 2, supplementary Tables S6 and S7,
available at Annals of Oncology online). Two important meth-
odological approaches were used to avoid two potential biases.
First, we assessed the predictive value of pCR in a multivariate
model after adjusting for other well-known EFS prognostic
factors [7, 8, 13]. Other studies have shown that tumours with a
better prognosis (e.g. smaller tumours) have a higher pCR rate.
The aim of our two-step approach multivariate analysis was to
correct for any such bias introduced by the different subtypes.
Second, we used a landmark approach when correlating pCR
with clinical end points, to avoid a bias known as guarantee-
time bias (GTB) [9, 10, 14]. Our concern in assessing survival
outcomes following pCR was to avoid a bias in favour of the
group of patients achieving pCR: this potential bias is known as
GTB and occurs when an analysis compares the survival of two
groups that are deﬁned by an event occurring after the start of
the follow-up period. In oncology, GTB is very well recognized
in the metastatic setting where the classic classifying event is ob-
jective response [9, 10], but a recently published paper has high-
lighted the importance of GTB in other settings including the
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Figure 1. Effect of pCR on EFS by intrinsic subtype (N = 1212 eligible and assessable patients). pCR, pathological complete response; EFS, event-free survival.
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neoadjuvant one [14]. In our study, we used a landmark analysis
which is a widely recommended approach to avoid GTB [9, 10,
14]. The ﬁndings we report within the context of a single
study have been conﬁrmed in the recent FDA meta-analysis
of 13 864 patients treated in prospective neoadjuvant chemo-
therapy trials [7].
There is an increased recognition of the need to consider
breast cancer as a collection of biologically different subtypes.
The results of the two-step multivariate analysis suggest a prog-
nostic impact of pCR on EFS across all subtypes even when
adjusting for subtypes. Our study has limitations. No central
pathology review of post-chemotherapy histology reports was
carried out. Such an analysis was conducted recently in the
context of a large multicentric trial and reported a 5% rate of
misclassiﬁcation involving pCR versus minimal residual disease
[15]. Notwithstanding these reassuring results, this analysis
highlights the need for consensus guidelines in the context of
prospective trials. No central review for grade, ER, PR and
HER2 was carried out. In addition, we could not use expression
arrays to distinguish between luminal A and B tumours, and
used the simpliﬁed classiﬁcation instead, as suggested by the St
Gallen 2011 consensus [11]. Reassuringly, the pCR rates
observed in the different intrinsic subtypes in our series, includ-
ing luminal A-like and B-like, were very similar to those
reported in a large German series or in the recent meta-analysis
where the same pCR deﬁnition was used [6, 7]. As with the
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Figure 1 Continued
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German series and FDA meta-analysis, we did not ﬁnd ﬁrm evi-
dence that pCR was univariately predictive of better outcomes
in luminal A-like tumours, though equally there was no evi-
dence that pCR had different prognostic effects between sub-
types as shown by the two-step multivariate analysis [6, 7]. We
have collected centrally the luminal A-like tumours and we are
in the process of analysing them at a molecular level, but we
suggest that the data are consistent with pCR being predictive ir-
respective of subtype.
Patients with pCR had excellent prognosis, particularly for
TN or luminal B/HER2-negative subgroups, and a correspond-
ingly poor prognosis for these subgroups when pCR was not
achieved. Given that all luminal B-like cases subsequently
received 5 years standard endocrine treatment, it is clear from
our data that a poor response to chemotherapy in this group
was still clinically relevant despite subsequent endocrine
therapy. Similar differences were observed in those patients with
HER2-positive tumours who went on to get post-surgical
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Figure 2. Effect of pCR on EFS by intrinsic subtype: univariate Cox regression models (N = 1212 eligible and assessable patients). pCR, pathological complete
response; EFS, event-free survival; HR, hazard ratio; CI, conﬁdence interval; HER2, human epidermal growth factor 2; df, degrees of freedom.
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adjuvant trastuzumab (supplementary Figure S5, available at
Annals of Oncology online). In other words, in this study,
achieving pCR remains a predictor of better survival despite the
use of post-surgical targeted therapies.
We chose to deﬁne pCR as complete disappearance of inva-
sive carcinoma in the primary tumour (or very few scattered
tumour cells) and in the nodes, while allowing for persistence of
DCIS. The recent FDA meta-analysis did not demonstrate a
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prognostic difference whether DCIS remains present or absent
in the absence of residual invasive cancer [7].
Given the known relationship between TP53 mutations and ER
status, the effect of TP53 function on pCR and survival outcomes
was assessed within each subtype [1]. In the univariate Cox
regression model, pCR predicts for a better EFS in all subtypes
irrespective of TP53 status (Figure 3). Furthermore, in the multi-
variate Cox regression model, in all subtypes except for HER2-
positive/non-luminal, patients with TP53-mutated tumours had
worse outcomes. The opposite result for HER2-positive/non-
luminal disease is probably a chance ﬁnding: this interaction
effect approaches signiﬁcance only for EFS (P = 0.1) (Table 2),
this subtype has the smallest number of patients and, among
those patients not receiving adjuvant trastuzumab, dispropor-
tionately more patients with wild-type TP53 relapsed 16 of 22
(72%), compared with those with mutant TP53 10 of 32 (31%).
In conclusion, this analysis of over 1200 cases within the
EORTC 10994/BIG 1-00 randomized phase III trial suggests
Table 2. Relationship between pCR, other important prognostic factors and EFS: a two-step multivariate Cox regression modela—HRs with 99% CI
(landmark method—N = 1212)
Factor HR (99% CI) P valueb
Age (years)
≤40 1.00 0.024
41–50 0.67 (0.46–0.98)
51–70 0.66 (0.35–1.25)
Menopausal status
Premenopausal 1.00 0.603
Postmenopausal 1.12 (0.63–1.99)
cT stage
T1–T2 1.00 <0.001
T3 1.82 (1.33–2.49)
T4 2.85 (1.89–4.31)
cN stage
N0 1.00 <0.001
N1 1.54 (1.13–2.10)
N2–N3 2.17 (1.18–4.00)
Histological type
Lobular 1.00 0.773
Ductal 0.93 (0.56–1.53)
Other 0.79 (0.34–1.84)
Pathological response
No pCR
pCR
1.00
0.40 (0.25–0.64)
<0.001
Treatment arm
FEC 1.00 0.004
T-ET 0.73 (0.54–0.97)
Intrinsic subtype
– – <0.001
TP53
– – 0.004
TP53 by intrinsic subtype
Wild type Mutated Not done or failurec 0.100
Luminal A-like 1.00 1.39 (0.75–2.55) 0.77 (0.34–1.75)
Luminal B-like (HER2 negative) 1.00 1.18 (0.52–2.68) 0.74 (0.20–2.65)
Luminal B-like (HER2 positive) 1.00 1.13 (0.60–2.16) 0.91 (0.41–2.00)
HER2 positive (non-luminal) 1.00 0.36 (0.15–0.85) 0.60 (0.24–1.52)
Triple negative 1.00 1.17 (0.53–2.59) 0.71 (0.26–1.94)
Note that while subtype and TP53 were included as main effects in the model, we have not reported HR effects as these are difﬁcult to interpret in the
presence of a signiﬁcant interaction between these terms.
aSee supplementary Figure S1, available at Annals of Oncology online.
bSigniﬁcance level α = 0.1 for interaction tests; α = 0.01 for main effects.
cTP53 not tested. The main reason was samples with <20% tumour cells.
pCR, Pathological complete response; EFS, event-free survival; HR, hazard ratios; CI, conﬁdence interval; FEC, 5-ﬂuorouracil, epirubicin and
cyclophosphamide; T-ET, docetaxel followed by epirubicin and docetaxel.
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that patients who achieve a pCR following six cycles of contem-
porary chemotherapy have signiﬁcantly better outcomes, irre-
spective of their intrinsic subtype and TP53 status. In contrast,
when chemotherapy does not induce a pCR, which is the case
for the majority of patients, outcomes are poorer. This observa-
tion across all subgroups justiﬁes the current interest in the de-
velopment of post-neoadjuvant trials, even in subgroups where
effective targeted therapies exist.
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